WallStSmart

Merck & Company Inc (MRK)vsWW International, Inc. Common Stock (WW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 9400% more annual revenue ($65.77B vs $692.33M). WW leads profitability with a 155.5% profit margin vs 13.6%. WW appears more attractively valued with a PEG of 4.92. WW earns a higher WallStSmart Score of 58/100 (C).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

WW

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 5.7Quality: 6.5
Piotroski: 6/9Altman Z: 5.10
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for WW.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

WW6 strengths · Avg: 10.0/10
P/E RatioValuation
1.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Return on EquityProfitability
405.4%10/10

Every $100 of equity generates 405 in profit

Profit MarginProfitability
155.5%10/10

Keeps 156 of every $100 in revenue as profit

EPS GrowthGrowth
5268.0%10/10

Earnings expanding 5268.0% YoY

Altman Z-ScoreHealth
5.1010/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WW4 concerns · Avg: 2.5/10
Market CapQuality
$185.48M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.763/10

Elevated debt levels

PEG RatioValuation
4.922/10

Expensive relative to growth rate

Revenue GrowthGrowth
-9.8%2/10

Revenue declined 9.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : WW

The strongest argument for WW centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 155.5% and operating margin at -16.9%.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : WW

The primary concerns for WW are Market Cap, Debt/Equity, PEG Ratio. Debt-to-equity of 1.76 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while WW is a declining play — different risk/reward profiles.

WW carries more volatility with a beta of 1.06 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

WW scores higher overall (58/100 vs 50/100), backed by strong 155.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

WW International, Inc. Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?